Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Stomach Neoplasms 4Carcinoma, Hepatocellular 3Solid Tumor 2Pancreatic Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1Neoplasms 1Multiple Primary Lung Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Melanoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Cervical Carcinoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Advanced Solid Tumours 1Advanced Solid Tumor 1Advanced Intrahepatic Cholangiocarcinoma 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

Nivolumab 7toripalimab 5Injections 5tislelizumab 3pembrolizumab 3spartalizumab 2sintilimab 2osimertinib 2Paclitaxel 2Ipilimumab 2Gemcitabine 2Cisplatin 2Carboplatin 2zimberelimab 1ulocuplumab 1sotorasib 1famitinib 1donafenib 1cemiplimab 1binimetinib 1avelumab 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Taxes 1SHR-1701 1Oxaliplatin 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1LY-2157299 1Immunotherapy, Adoptive 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumor × sintilimab × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Fujian Haixi Pharmaceuticals Co., Ltd.

Phase 1/2 Active not recruiting
155 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡